U.S. Markets
FDA approves Lilly's (LLY) Onswik, a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
StockNow breaking-news AI analysis
The US FDA approved Eli Lilly's Onswik, a once-weekly basal insulin injection treatment designed for adult patients living with type 2 diabetes.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
